Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company ...

Ipsen notified Hutchmed that it was "voluntarily" withdrawing the drug from US markets, prompting Hutchmed to recall Tazverik in China, Hong Kong and Macau. It is also discontinuing all active ...

Katrina Robinson wants to help son Lewis enjoy what time he has left ...

Lilly Warren, whose family benefited in 2018, now volunteers with Inheritance of Hope at its Legacy Retreats for families ...

PARIS, FRANCE, 09 March 2026 ? Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...

PARIS, FRANCE, 09 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...

Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary ...

In alignment with this commitment, HUTCHMED Limited has promptly informed healthcare professionals, the China National Medical Products Administration (“NMPA”), the Hong Kong Department of Health and ...

Chen, M.Y. and Luo, L.P. (2026) CT and MRI Findings of Epithelioid Hemangioma of Bone: A Case Report. Journal of Biosciences and Medicines, 14, 246-252. doi: 10.4236/jbm.2026.143018 .

The Independent Data Monitoring Committee overseeing the Phase Ib/III SYMPHONY-1 trial, which was testing Tazverik alongside lenalidomide and rituximab, determined that adverse ev ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

By Tarun Sai Lomte Scientists reveal how evolution within our own tissues can drive disease, protect cells, and uncover hidden therapeutic targets for future precision medicine. Somatic genomics ...